Status:
COMPLETED
Citrulline and Arginase Activity in Severe Sepsis and Septic Shock
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Intensive Care Units
Infection
Eligibility:
All Genders
18+ years
Brief Summary
Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated wit...
Eligibility Criteria
Inclusion
- 18 years old or older
- Patient admitted to ICU
- Diagnosis, suspected or confirmed, of severe sepsis or septic shock
- Expected ICU stay of at least 2 days
- Affiliation to a social security system or recipient of a such system
- Signed informed consent
Exclusion
- Pregnancy
- Chronic intestinal pathology
- Chronic renal failure defined by creatinine clearance \<50 ml / min / 1.73m2 (CKD-EPI)
- Severe hepatic insufficiency (Child-Pugh stage C score)
- Legal incapacity or limited legal capacity
- Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator
- Patient within the exclusion period of another study or planned by the "national file of volunteers"
Key Trial Info
Start Date :
May 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2022
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT03837730
Start Date
May 28 2019
End Date
October 30 2022
Last Update
January 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de BESANCON
Besançon, France, 25030